Clinical trials: Systemic Lupus
SLE (Systemic Lupus)
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity
- Trial name
- NCT06610409
- Testing
- blood sampling
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Fibromyalgia, Lupus Erythematosus, Systemic
Brief Pain Exposure Therapy (BPET) For Nociplastic Pain
This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability…
- Conditions
- Fibromyalgia, Lupus Erythematosus, Systemic, Chronic Pelvic Pain, Chronic Low Back Pain (CLBP)
- Trial name
- BPET (NCT06208514)
- Testing
- Brief pain exposure therapy (BPET)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Michigan
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- EMBODY2 (NCT01261793)
- Testing
- Epratuzumab
- Where
- 133 sites in United States, Brazil and 14 more
- Volunteers
- 791 people
- Sponsor
- UCB Pharma
Lupus
Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire
The evaluation of lupus patients must include several approaches, in particular disease activity and quality of life. The Systemic Lupus Activity Questionnaire (SLAQ) is a validated self-questionnaire to evaluate disease…
- Trial name
- FRESH COLA (NCT02857452)
- Testing
- SLA Questionnaire, Lupus Qol Questionnaire
- Where
- France
- Volunteers
- 162 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE).
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
- Trial name
- AERIS (NCT07260877)
- Testing
- VENT-03
- Where
- 34 sites in United States, Bulgaria and 6 more
- Volunteers
- 24 people
- Sponsor
- Ventus Therapeutics U.S., Inc.
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lupus Nephritis
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important impact on morbidity and mortality. Renal biopsy is the "gold standard" for the diagnosis of LN, however, it is an invasive technique, not…
- Trial name
- NCT04534647
- Testing
- different serum and urine biomarkers
- Where
- Argentina
- Volunteers
- 100 people
- Sponsor
- Liga Panamericana de Asociaciones de Reumatologia (PANLAR)
Systemic Lupus Erythematosus
Study of Epratuzumab in Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
- Trial name
- NCT00111306
- Testing
- epratuzumab
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 510 people
- Sponsor
- UCB Pharma
Nephritis, Systemic Lupus Erythematosus
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, multiple dose escalation study, enrolling approximately 48 subjects.
- Trial name
- NCT00818948
- Testing
- AMG 811
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
The purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia
- Trial name
- NCT05929248
- Testing
- Telitacicept, conventional therapy
- Volunteers
- 64 people
- Sponsor
- Guanmin Gao
SLE
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
The aim of this study is to correlate the autoantibody against oxidized LDL with disease activity and cardiovascular affection in patients with SLE.
- Trial name
- NCT05479071
- Testing
- Blood test
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the safety and tolerability of TAK-079 in comparison with matching placebo, administered once every 3 weeks over a 12-week dosing period in participants with active SLE who are receiving…
- Trial name
- NCT03724916
- Testing
- TAK-079
- Where
- 19 sites in United States
- Volunteers
- 23 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lupus Erythematosus, Systemic
Evaluation of the Influence of Food Regimen on Oshadi D Absorption
The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects.
- Trial name
- NCT01327352
- Testing
- Oshadi D
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oshadi Drug Administration
Systemic Lupus Erythematosus
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
The potential role of vitamin D on disease susceptibility, activity and severity has been considered for several autoimmune rheumatologic diseases include systemic lupus erythematosus (SLE) .
- Trial name
- NCT01892748
- Testing
- Cholecalciferol
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- ROSA MARIA RODRIGUES PEREIRA
Lupus Nephritis
Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital
study epidemiology of lupus nephritis patients admitted to nephrology unit inward or in outpatient clinic in Assiut Nephrology Unit
- Trial name
- NCT05120882
- Volunteers
- 60 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE)
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to…
- Trial name
- NCT03656562
- Testing
- VAY736, CFZ533
- Where
- 31 sites in Argentina, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Systemic Sclerosis
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06379646
- Testing
- YTS109
- Where
- China
- Volunteers
- 6 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Lupus Erythematosus, Systemic
The Effect of Clinical Pilates Training on Fatigue, Emotional State, Functional Capacity, Sleep and Quality of Life in Women With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, autoimmune, inflammatory disease with the potential to affect any organ in the body.
- Trial name
- NCT07394361
- Testing
- Clinical Pilates Training, Home exercise program
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Emir İbrahim IŞIK
Gout, Rheumatoid Arthritis
Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher…
- Conditions
- Gout, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus
- Trial name
- CAPTAIN (NCT05927688)
- Testing
- Therapeutic management following access by the physician to his patient's ePROs
- Where
- France
- Volunteers
- 352 people
- Sponsor
- University Hospital, Strasbourg, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.